Trevi Therapeutics (TRVI) Q4 Loss Narrows to $0.06/Share vs $0.10 Estimate, 37% Better Than Expected
Trevi Therapeutics narrows Q4 loss to $0.06 per share, beating estimates by 37% as the pre-revenue biotech maintains unanimous analyst support.
5 articles, transcripts, and reports
Trevi Therapeutics narrows Q4 loss to $0.06 per share, beating estimates by 37% as the pre-revenue biotech maintains unanimous analyst support.
Trevi Therapeutics, Inc (NASDAQ: TRVI) Q4 2021 Earnings Conference
Trevi Therapeutics, inc (NASDAQ: TRVI) Q3 2021 Earnings Conference
Trevi Therapeutics, inc (NASDAQ: TRVI) Q2 2021 Earnings Conference
Trevi Therapeutics, inc (NASDAQ: TRVI) Q4 2020 Earnings Conference